Oculis Holding AG

Research Oculis Holding AG (OCS) on Bullrun: market cap USD 514.85M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

TickerOCS
ExchangeNASDAQ
CountrySwitzerland
SectorHealthcare
IndustryBiotechnology
CurrencyUSD
Market capUSD 514.85M
Financial periodQ2 2026
RevenueCHF 0
Net income-CHF 9.97M
Free cash flow-CHF 20.25M

Valuation Snapshot

latest market cap is USD 514.85M.

Five-year financial history

Year	Revenue	Net income	Free cash flow	Gross margin	Diluted EPS	Cash	Total debt	Equity
FY2025	CHF 0	-CHF 98.96M	-CHF 67.69M	n/a	-1.89	CHF 81.33M	CHF 2.31M	CHF 196.07M
FY2024	CHF 0	-CHF 85.78M	-CHF 49.15M	n/a	-2.12	CHF 27.71M	CHF 1.18M	CHF 73.38M
FY2023	CHF 0	-CHF 88.80M	-CHF 55.09M	n/a	-2.97	CHF 38.33M	CHF 605.00K	CHF 93.73M
FY2022	CHF 0	-CHF 38.70M	-CHF 28.62M	n/a	-11.32	CHF 19.79M	CHF 633.00K	-CHF 97.99M

Valuation history

Year	Snapshot date	Market cap	P/E	Dividend yield	Annual dividend/share
2026	2026-10-09	USD 514.85M	n/a	n/a	n/a
2025	2025-12-31	USD 1.16B	n/a	n/a	n/a
2024	2024-12-31	USD 742.26M	n/a	n/a	n/a
2023	2023-12-29	USD 409.17M	n/a	n/a	n/a
2022	2022-09-29	n/a	198.2	n/a	n/a
2021	2021-12-31	n/a	107.7	n/a	n/a

About Oculis Holding AG

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease;

Related stock research

Switzerland stocks Switzerland Healthcare stocks A-Z stock index

Other Healthcare stocks

AC Immune SA (ACIU) Addex Therapeutics Ltd (ADXN) Bachem Holding AG (BANB) BB Biotech AG (BION.SW) Bioversys AG (BIOV) Basilea Pharmaceutica AG (BSLN) CRISPR Therapeutics AG (CRSP) Idorsia Ltd (IDIA) MoonLake Immunotherapeutics - Class A (MLTX) MindMaze Therapeutics Holding SA (MMTX.SW) Molecular Partners AG (MOLN) NLS Pharmaceutics Ltd (NCEL)

Frequently asked questions

What is Oculis Holding AG's market cap?

Oculis Holding AG's market capitalization is USD 514.85M.

What does Oculis Holding AG do?

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally.